PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30940770-2	2019	High-dose OCS reduced median blood eosinophils (-60 cells/microl; 95% CI -140 to 10), periostin (-8.4 ng/mL; -11.6 to -2.8), FeNO (-19.0 ppb; -28.5 to -4.0), IL-5 (-0.17 pg/mL; -0.28 to -0.08) and IL-13 (-0.15 pg/mL; -0.27 to -0.03).	L-Cysteic acid	10-13	interleukin 5	Homo sapiens	158-162	
35487369-1	2022	BACKGROUND: Reslizumab, a biologic targeting interleukin-5 has been shown to reduce asthma exacerbations and maintenance oral corticosteroid (OCS) use in randomized controlled trials and pre-post studies in patients with severe eosinophilic asthma.	L-Cysteic acid	142-145	interleukin 5	Homo sapiens	45-58